Catalogue: Resources for COVID-19 and influenza vaccine development
A panel of SARS-CoV-2 reagents (e.g. antigens, antibodies, and kits) and influenza antigens have been developed to support the development of vaccines.
To support the development of COVID-19 and influenza vaccine, Sino Biological has developed a large collection of SARS-CoV-2 reagents, including recombinant antigens, recombinant mutants, neutralising antibodies, and specific antibodies as well as 630+ HA, NA, and ME antigens from over 250 strains of influenza viruses, including vaccine strains and the pandemic strains.